Telix Pharmaceuticals Limited (TLX) Stock Overview
Explore Telix Pharmaceuticals Limited’s financial performance, market position, analyst ratings, and future outlook.
Telix Pharmaceuticals Limited (TLX)
Key Financials
Key Financials
Market Cap
3.5B
P/E Ratio
-467.40
EPS (TTM)
$-0.02
ROE
-0.02%
TLX Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Telix Pharmaceuticals Limited (TLX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of C+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 43.67, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $1.06.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -467.40 and a market capitalization of 3.5B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.